Loading organizations...
§ Private Profile · Leiden, Zuid-Holland, The Netherlands
Preclinical biotech company developing small molecule therapeutics targeting WASp to inhibit cancer cell growth in blood cancers.
BIMINI Biotech is a preclinical biotechnology company based in Leiden, Netherlands, that develops first-in-class small molecule therapeutics targeting the Wiskott Aldrich Syndrome Protein to inhibit cancer cell growth in blood cancers like lymphoma and leukemia. The organization's proprietary portfolio of modulators originated from a strategic patent collaboration with the Institute of Oncology Research to address unmet medical needs in hematological oncology and potential autoimmune disorders. To support its preclinical drug development pipeline, the enterprise has secured over €40 million in total financing, which includes substantial non-dilutive scientific research grants from various institutions. In January 2025, the company closed a €3 million seed funding round backed by lead investor Torrey Pines Investment, alongside participation from InnovationQuarter Capital and Libertatis Ergo Holding. BIMINI Biotech was founded in 2019 by co-founders Digvijay Gahtory and Maurits van den Nieuwboer.
BIMINI Biotech has raised $3.5M across 1 funding round.
BIMINI Biotech has raised $3.5M in total across 1 funding round.
BIMINI Biotech has raised $3.5M across 1 funding round. Most recently, it raised $3.5M Seed in January 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 13, 2025 | $3.5M Seed | Torrey Pines Investment | — | Announced |
BIMINI Biotech has raised $3.5M in total across 1 funding round.
BIMINI Biotech's investors include Torrey Pines Investment.